# Medical Model Evaluation Results

This file provides quick navigation to the responses generated by each model for the 20 medical questions.

| ID | Question Snippet | PMC-LLaMA 13B | GPT-4o | Gemini 3 Pro | MedGemma 27B | Perplexity |
|:--:|:-----------------|:---:|:---:|:---:|:---:|:---:|
| **1** | Which gene mutations (pro... | [View](axiong_PMC_LLaMA_13B/1.md) | [View](gpt-4o/1.md) | [View](gemini-3-pro-preview/1.md) | [View](google_medgemma-27b-text-it/1.md) | [View](perplexity/1.md) | 
| **2** | Which mutations, if any, ... | [View](axiong_PMC_LLaMA_13B/2.md) | [View](gpt-4o/2.md) | [View](gemini-3-pro-preview/2.md) | [View](google_medgemma-27b-text-it/2.md) | [View](perplexity/2.md) | 
| **3** | Which resistance mechanis... | [View](axiong_PMC_LLaMA_13B/3.md) | [View](gpt-4o/3.md) | [View](gemini-3-pro-preview/3.md) | [View](google_medgemma-27b-text-it/3.md) | [View](perplexity/3.md) | 
| **4** | What percentage of metast... | [View](axiong_PMC_LLaMA_13B/4.md) | [View](gpt-4o/4.md) | [View](gemini-3-pro-preview/4.md) | [View](google_medgemma-27b-text-it/4.md) | [View](perplexity/4.md) | 
| **5** | Are these resistance patt... | [View](axiong_PMC_LLaMA_13B/5.md) | [View](gpt-4o/5.md) | [View](gemini-3-pro-preview/5.md) | [View](google_medgemma-27b-text-it/5.md) | [View](perplexity/5.md) | 
| **6** | Is there a subset of brea... | [View](axiong_PMC_LLaMA_13B/6.md) | [View](gpt-4o/6.md) | [View](gemini-3-pro-preview/6.md) | [View](google_medgemma-27b-text-it/6.md) | [View](perplexity/6.md) | 
| **7** | Multiple mutations are al... | [View](axiong_PMC_LLaMA_13B/7.md) | [View](gpt-4o/7.md) | [View](gemini-3-pro-preview/7.md) | [View](google_medgemma-27b-text-it/7.md) | [View](perplexity/7.md) | 
| **8** | Where do mutation pattern... | [View](axiong_PMC_LLaMA_13B/8.md) | [View](gpt-4o/8.md) | [View](gemini-3-pro-preview/8.md) | [View](google_medgemma-27b-text-it/8.md) | [View](perplexity/8.md) | 
| **9** | Is there a correlation be... | [View](axiong_PMC_LLaMA_13B/9.md) | [View](gpt-4o/9.md) | [View](gemini-3-pro-preview/9.md) | [View](google_medgemma-27b-text-it/9.md) | [View](perplexity/9.md) | 
| **10** | How long, on average, doe... | [View](axiong_PMC_LLaMA_13B/10.md) | [View](gpt-4o/10.md) | [View](gemini-3-pro-preview/10.md) | [View](google_medgemma-27b-text-it/10.md) | [View](perplexity/10.md) | 
| **11** | Does Oncotype Dx, or the ... | [View](axiong_PMC_LLaMA_13B/11.md) | [View](gpt-4o/11.md) | [View](gemini-3-pro-preview/11.md) | [View](google_medgemma-27b-text-it/11.md) | [View](perplexity/11.md) | 
| **12** | How do resistance pattern... | [View](axiong_PMC_LLaMA_13B/12.md) | [View](gpt-4o/12.md) | [View](gemini-3-pro-preview/12.md) | [View](google_medgemma-27b-text-it/12.md) | [View](perplexity/12.md) | 
| **13** | Does radiotherapy alter g... | [View](axiong_PMC_LLaMA_13B/13.md) | [View](gpt-4o/13.md) | [View](gemini-3-pro-preview/13.md) | [View](google_medgemma-27b-text-it/13.md) | [View](perplexity/13.md) | 
| **14** | What is the resistance me... | [View](axiong_PMC_LLaMA_13B/14.md) | [View](gpt-4o/14.md) | [View](gemini-3-pro-preview/14.md) | [View](google_medgemma-27b-text-it/14.md) | [View](perplexity/14.md) | 
| **15** | In the neoadjuvant settin... | [View](axiong_PMC_LLaMA_13B/15.md) | [View](gpt-4o/15.md) | [View](gemini-3-pro-preview/15.md) | [View](google_medgemma-27b-text-it/15.md) | [View](perplexity/15.md) | 
| **16** | Is there data in the lite... | [View](axiong_PMC_LLaMA_13B/16.md) | [View](gpt-4o/16.md) | [View](gemini-3-pro-preview/16.md) | [View](google_medgemma-27b-text-it/16.md) | [View](perplexity/16.md) | 
| **17** | What therapeutic options ... | [View](axiong_PMC_LLaMA_13B/17.md) | [View](gpt-4o/17.md) | [View](gemini-3-pro-preview/17.md) | [View](google_medgemma-27b-text-it/17.md) | [View](perplexity/17.md) | 
| **18** | How does stereotactic abl... | [View](axiong_PMC_LLaMA_13B/18.md) | [View](gpt-4o/18.md) | [View](gemini-3-pro-preview/18.md) | [View](google_medgemma-27b-text-it/18.md) | [View](perplexity/18.md) | 
| **19** | Are there any non-traditi... | [View](axiong_PMC_LLaMA_13B/19.md) | [View](gpt-4o/19.md) | [View](gemini-3-pro-preview/19.md) | [View](google_medgemma-27b-text-it/19.md) | [View](perplexity/19.md) | 
| **20** | Can hyper- or hypo-fracti... | [View](axiong_PMC_LLaMA_13B/20.md) | [View](gpt-4o/20.md) | [View](gemini-3-pro-preview/20.md) | [View](google_medgemma-27b-text-it/20.md) | [View](perplexity/20.md) | 
